Selected article for: "Lassa virus and LASV Lassa virus"
Author: Lukashevich, Igor S.; Paessler, Slobodan; de la Torre, Juan Carlos
Title: Lassa virus diversity and feasibility for universal prophylactic vaccine
  • Cord-id: qjlhoi7l
  • Document date: 2019_1_31
    • ID: qjlhoi7l
    Snippet: Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, Mastomys natalensis, which is widely spread in sub-Saharan Africa. LASV infection of humans can cause Lassa fever (LF), a disease associated with high morbidity and significant mortality. Recent evidence indicates an LASV expansion outside its traditional endemic areas. In 2017, the World Health Organization (WHO) included LASV in top-priority pathogens and r
    Document: Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, Mastomys natalensis, which is widely spread in sub-Saharan Africa. LASV infection of humans can cause Lassa fever (LF), a disease associated with high morbidity and significant mortality. Recent evidence indicates an LASV expansion outside its traditional endemic areas. In 2017, the World Health Organization (WHO) included LASV in top-priority pathogens and released a Target Product Profile (TPP) for vaccine development. Likewise, in 2018, the US Food and Drug Administration added LF to a priority review voucher program to encourage the development of preventive and therapeutics measures. In this article, we review recent progress in LASV vaccine research and development with a focus on the impact of LASV genetic and biological diversity on the design and development of vaccine candidates meeting the WHO’s TPP for an LASV vaccine.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and acute respiratory distress: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • abdominal pain and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • abdominal pain and liver involvement: 1, 2, 3, 4, 5, 6, 7, 8
    • abdominal pain and liver pathology: 1
    • abdominal pain and low moderate: 1, 2
    • abdominal pain and lymphocytic choriomeningitis virus: 1
    • accelerated vaccine development and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acceptable safety and acute respiratory distress: 1
    • acceptable safety and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acceptable safety and additional evidence: 1
    • acute respiratory distress and additional evidence: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory distress and liver involvement: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory distress and liver pathology: 1
    • acute respiratory distress and long term protection: 1, 2, 3
    • acute respiratory distress and low moderate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory distress and lymphocytic choriomeningitis virus: 1
    • acute respiratory syndrome and additional evidence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28